Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lonafarnib · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Lonafarnib plus Anastrozole | EXPERIMENTAL | Participants receive lonafarnib 200 mg orally (PO) twice per day (BID) beginning on Day 1 Cycle 1 and continuing until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole 1 mg, PO, once per day (QD) for as long as the participant is receiving lonafarnib |
| Placebo plus Anastrozole | ACTIVE_COMPARATOR | Participants receive placebo to lonafarnib PO BID beginning on Day 1 Cycle 1 until Progression of Disease, unacceptable toxicity, or other discontinuation criteria are met; and anastrozole, 1mg PO QD for as long as the participant is receiving placebo |
| Name | Type | Description |
|---|---|---|
| Lonafarnib | DRUG | - |
| Placebo | DRUG | - |
| anastrozole | DRUG | - |
Inclusion Criteria: * Postmenopausal women who have histologically-confirmed breast cancer with the following characteristics: * estrogen and/or progesterone receptor positive, * locally advanced disease * distant metastatic disease, stage 4 * Subjects eligible for single-agent treatment wit...
Top 20 of 92 competitors
Lonafarnib is an investigational small molecule being studied for the treatment of breast cancer. It is being evaluated in combination with anastrozole for advanced breast cancer in female patients. The drug is currently in Phase 2 clinical development and is not approved for any use.
Lonafarnib is a small molecule that targets farnesyltransferase, an enzyme involved in protein prenylation. By inhibiting this enzyme, it may disrupt signaling pathways that contribute to cancer cell growth. This mechanism is being explored in the context of advanced breast cancer.
Lonafarnib is being developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in breast cancer.
Lonafarnib is in Phase 2 clinical development for breast cancer. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under investigation for this indication.
Lonafarnib has been studied in one completed Phase 2 clinical trial, identified as NCT00081510. This randomized, double-blind, active-controlled trial enrolled 110 female participants with advanced breast cancer and evaluated the combination of anastrozole plus lonafarnib compared to anastrozole plus placebo.
Yes, Lonafarnib is also known as SCH 66336. The clinical trial NCT00081510, which studied the drug for advanced breast cancer, refers to it as SCH 66336 in the trial title. Both names refer to the same investigational compound.